Bookmark
Forward
QuickView for Ropinirole (compound)
PubChem
| Name: | ropinirole |
|---|---|
| PubChem Compound ID: | 5095 |
| Molecular formula: | C16H24N2O |
| Molecular weight: | 260.375 g/mol |
| Synonyms: |
Ropinirole; Ropinirolum [INN-Latin]; Lopac-R-4152; 91374-21-9; 2H-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-; NCGC00015893-01; C07564; 91374-20-8; ReQuip; Ropinirol [INN-Spanish]
|
DrugBank
Identification
| Name: | ropinirole |
|---|---|
| Name (isomeric): | DB00268 |
| Drug Type: | small molecule |
| Synonyms: |
Ropinirolum [INN-Latin]; Ropinirole hydrochloride; Ropinirole HCl; Ropinirol [INN-Spanish]
|
| Brand: | ReQuip CR, Requip, ReQuip XL |
| Category: | Antidyskinetics, Antiparkinson Agents, Dopamine Agonists, Central Nervous System Agents |
| CAS number: | 91374-21-9 |
Pharmacology
| Indication: | For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome. |
|---|---|
| Pharmacology: |
Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is u...
show more » |
| Mechanism of Action: |
Ropinirole binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have d...
show more » |
| Absorption: | Absolute bioavailability is 55%, indicating a first pass effect. Food does not affect the extent of absorption. |
| Protein binding: | 40% bound to plasma proteins with a blood-to-plasma ratio of 1:1. |
| Biotransformation: | Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%). |
| Route of elimination: | Ropinirole is extensively metabolized by the liver to inactive metabolites, and less than 10% of the administered dose is excreted as unchanged drug in urine. |
| Half Life: | 6 hours |
| Clearance: | 47 L/hr [after oral administration to Parkinson's disease patients and patients with Restless Legs Syndrome] |
| Toxicity: | Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
Enzymes
